The rise of GLP-1 medications, like Wegovy and Eli Lilly’s Foundayo, is reshaping the U.S. apparel market as more consumers experience significant weight loss. With nearly 13% of U.S. adults currently on these drugs, fashion retailers are poised to capitalize on a growing demand for new clothing, as users anticipate needing new wardrobes due to size changes. Analysts from Bernstein estimate that this trend could translate to an additional $13 billion in annual apparel spending, driven by the projected increase in GLP-1 users over the coming years.
As consumers shift from larger sizes to smaller ones, sales in categories like intimate apparel are already reflecting these changes. Retailers such as Stitch Fix have reported a surge in customer requests related to weight loss, indicating a clear market opportunity. The broader apparel sector, which has faced sluggish growth, may find a much-needed boost from this demographic shift.
For market professionals, the key takeaway is to monitor how retailers adapt to this evolving consumer base. Brands that effectively address the emotional and physical transformations of GLP-1 users could capture significant market share, particularly in off-price and athletic apparel segments.
Source: cnbc.com